Answers are grounded in this paper and cite their sources.
Written guidance is the usual instrument for moving new evidence into practice, but its contribution is rarely measurable, because prescribing data and dated guideline texts are seldom available together. Uzbekistan’s first COVID-19 wave provides both. We measured when prescribing changed relative to international evidence and to dated national guidance; we did not measure the mechanisms by which either reached the ward. Interrupted time-series analysis of all 2433 patients admitted to a designated COVID-19 hospital in Tashkent between 11 April and 10 August 2020, linked to the dated national interim guidance in force. For dexamethasone, anticoagulants, hydroxychloroquine, azithromycin and any antibiotic (a prespecified negative control), change points were located at daily resolution by profile likelihood with bootstrap intervals, and segmented logistic regression was fitted with adjustment for age, sex, comorbidity, severity and asymptomatic status. Patients are located in time by admission date. Among patients admitted from 16 June 2020, the day the RECOVERY result was announced, dexamethasone prescribing rose from 1.1% to 54.3%, reaching 77.1% while the guidance in force advised against routine corticosteroids. Hydroxychloroquine and azithromycin did not change at the WHO announcement of 17 June − 90.0% of patients admitted in the following four weeks still received hydroxychloroquine - and changed among patients admitted from 20 July, seven days after national withdrawal took effect (hydroxychloroquine 91.1% to 16.2%; azithromycin 93.6% to 44.8%). When guidance reinstated hydroxychloroquine on 31 July, prescribing did not return (5.3%). Anticoagulation, recommended nationally since March, changed only from 15 July (8.7% to 76.6%). The negative control did not change. Evidence, national guidance and prescribing practice moved on markedly different timelines for adoption, de-adoption and attempted re-adoption within one hospital. De-adoption was temporally associated with national withdrawal rather than with the international evidence; adoption of dexamethasone preceded and for a period ran against the guidance in force; reinstatement was not followed. The organizational mechanisms behind these differences - who decided, what authority guidance carried, how it reached the ward - were not measured and are the priority for future work.
No takes yet. Share an insight, caveat, or question.
Rakhimov et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: